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Old age is recognized to be the commonest time in life to develop epilepsy. There is a perception that older patients are 
more sensitive to the deleterious cognitive ffects of antiepileptic drugs (AEDs). Elderly patients (median age 70 years, range 
60-88 years) taking anticonvulsant monotherapy (10 carbamazepine [CBZ], 8 sodium valproate [VPA], 5 phenytoin [PHT]) 
took an extra dose of their usual medication (200mg CBZ, 500mg VPA, 100mg PHT) and matched placebo each for a month 
in random order. The concentrations of AEDs were higher after 7 and 28 days of active treatment compared with placebo (7 
days: CBZ 9.5 vs. 7.8 mg L - I ,  p < 0.05; VPA 97 vs. 64 mg L - l ,  p < 0.05; PHT 13 vs. I1 mg L - I ,  p < 0.05; 28 days: 
CBZ 9.4 vs. 7.7 mg L- I ;  p < 0.01, VPA 85 vs. 60 mg L - l ,  p < 0.05; PHT 16 vs. 13 mg L - l ,  p < 0.05). Despite these 
increases in concentration, there were no significant changes in attention, reaction time, finger tapping, memory, side-effect 
scale or sedation scoring during the active phases compared with placebo phases for the three drugs analysed together and 
separately. Elderly patients taking standard AEDs as monotherapy did not develop cognitive impairment when the dose was 
modestly increased within the target range for each drug. 
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INTRODUCTION 
Epilepsy is a major cause of morbidity in the elderly I . 
Several studies have shown that there is an age- 
related increase in it prevalence, resulting in epilepsy 
ranking as the third commonest neurological disorder 
(after stroke and dementia) in patients over 60 years 
of age 2'3. Factors associated with the development 
of a seizure disorder in this population include the 
increasing likelihood of cerebrovascular disease, cere- 
bral tumours and metabolic/toxic events 4. With the 
expanding elderly population, the number of older pa- 
tients having epilepsy can be expected to rise 5. There 
are few studies exploring AED efficacy and toxicity 
in the elderly 6'7. As a result, dosing schedules are 
based on the results of trials in younger patients. 
Treatment involves balancing optimal seizure con- 
trol against susceptibility to adverse effects taking 
into consideration concomitant disease, drug interac- 
tions and the physiological changes associated with 
ageing that result in altered pharmacokinetics and 
pharmacodynamics 8. 
* E-maih Mart in .  J. B rod ie@c l inmed.  gla. ac. uk  
1059-1311/98/020159 + 04 $12.00/0 
The potential for deleterious effects of AEDs on 
cognitive function in the elderly is of particular im- 
portance. The incidence and severity of cognitive 
impairment rises sharply with age. In younger pa- 
tients, there has been a plethora of studies explor- 
ing the relationship of seizures, AEDs, underlying 
pathology with cognition 9-11 . Polypharmacy has been 
recognized as increasing the likelihood of impair- 
ment, as does, not surprisingly, higher doses and 
plasma concentrations of AEDs 12-j7. Early studies 
supported the hypothesis that individual AEDs var- 
ied in their propensity to cause cognitive adverse ef- 
fects, but more recent research suggests that, at equiv- 
alent serum concentrations, phenobarbital, phenytoin 
(PHT), carbamazepine (CBZ), oxcarbazepine and val- 
proic acid (VPA) can all produce cognitive impair- 
ment to a similar extent l°. Different cognitive modal- 
ities can, however, be affected by different AEDs 18. 
Fewer studies have compared the cognitive conse- 
quences of increased doses of AEDs m-21. We have 
sought to examine the cognitive abilities of elderly 
patients with epilepsy, before, during and after an in- 
crease in their monotherapy doses of CBZ, VPA or 
PHT using a double-blind, placebo-controlled design. 
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Table 1 : Mean [SEM] antiepileptic drug concentrations (ranges) at each time period during adjunctive active and placebo 
treatment. 
Carbamazepine Sodium valproate Phenytoin 
Visit n Active Placebo n Active Placebo n Active Placebo 
Baseline 10 7.6 7.7 8 63 65 5 9.9 12 
[0.5] [0.4] [6.1] [7.6] [1.6] [I.31 
(6.1-11) (5.7-9.1) (39-87) (35-85) (3.4-12) (9.9-16) 
Day 1 10 8.5 7.5 8 71 62 5 10 12 
[0.5] I0.41 [7.61 I7.61 [1.41 II.6] 
(7.2-11) (6.6-9.9) (62-85) (36-82) (5-14) (9.2-18) 
Day 7 10 9.5* 7.8 8 97* 64 5 13" 11 
[0.5] [0.5] [5.5] [9.1l [0.9] ll.1] 
(7.7-12) (6.1-9.7) (72-112) (35-76) (11-16) (8-15) 
Day 28 10 9.4** 7.7 8 85* 60 5 16" 13 
[0.3] [0.61 [101 19.01 [I.71 [I.8] 
(8.1-11) (6.2-10) (47-123) (46-86) (12-21) (9.3-18) 
All results are expressed in mg L -1 . 
* p < 0.05. 
** p < 0.01. 
METHODS 
Patients 
Twenty-three patients (11 female, 12 male) with a 
mean age of 70 years (range 60-88 years) were re- 
cruited from the epilepsy clinic at the Western In- 
firmary in Glasgow. All were receiving stable regi- 
mens of CBZ, VPA or PHT as monotherapy with no 
change in dosing over the preceding three months. 
Seventeen patients had a mean (range) seizure fre- 
quency of one (1-10) per month in the three months 
prior to the study, with six patients being seizure-free 
during this period. All recruited patients completed 
the study. Patients were required to score more than 
7 on the MEAMS dementia screening test to ensure 
participation. The study had the approval of the West- 
ern Ethical Committee and all patients gave written 
informed consent. 
Protocol 
At the initial visit, patients completed a self- 
assessment questionnaire providing details of their 
epilepsy and its treatment. Seizure frequency and de- 
scriptions were recorded on standard seizure charts. 
Each underwent a battery of cognitive function tests. 
A 20 ml blood sample was withdrawn for AED con- 
centrations. Patients were randomized to receive ei- 
ther an extra dose of their usual medication (200 mg 
CBZ, 500 mg VPA, 100 mg PHT) or matched placebo 
in a double-blind fashion for 28 days. After a 2-week 
washout period, they were transferred to the alterna- 
tive treatment for a further 4 weeks. Patients were 
monitored on days 1, 7 and 28 of both study pe- 
riods. On each occasion, blood was withdrawn for 
anticonvulsant assay and the cognitive function test 
battery was repeated at the same time since dosing on 
each occasion. At the final visit, seizure charts were 
reviewed. Patients were asked which treatment they 
preferred. Those who benefited from an increased 
dose of their medication remained on it. 
Cognitive function testing 
A standard battery of cognitive function tests was 
performed as detailed by Gillham et al 2°. These tests 
have been widely employed in a range of previously 
published studies investigating the cognitive ffects of 
AEDs 15-22. A brief summary of the individual tests 
is given below. 
Intelligence. Verbal IQ was calculated from the score 
on the National Adult Reading Test. Performance IQ 
was measured by a standard method using the score 
on Raven's standard progressive matrices. 
Threshold detection. Each patient was shown a vari- 
ety of rectangles on a visual display unit. After a very 
short period of time, an additional rectangle appeared 
on the screen. The 'threshold' was the minimum time 
period from the presentation of the rectangle display 
and the appearance of the additional rectangle, which 
the patient required to identify its presence. 
Choice reaction time. This test was based on the 
choice reaction time facility of the Leeds psychomo- 
tor tester. It was defined as the time taken in millisec- 
onds to move the index finger from a base marker and 
Cognitive effects of anticonvulsant monotherapy in elderly patients 
Table 2: Selected mean (SEM) reaction, memory, attention and symptomatology scores before and after 28 days of both 
treatments. 
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Reaction Memory Attention Symptomatology 
Choice 
reaction 
decision Digit span Visual span Word-pair Threshold task 
time (ms) forward backward learning (flame units) Concentration Mood 
CBZ--baseline 0.6 (0.1) 6.6 (0.4) 2.9 (0.4) 10 (I.8) 1.9 (0.4) 3.2 (1.1) 1.2 (0.7) 
CBZ--placebo 0.6 (0.1) 6.4 (0.5) 3.0 (0.2) 11 (1.1) 1.6 (0.5) 2.6 (1.0) 1.5 (0.9) 
CBZ---active 0.6 (0.1) 6.4 (0.5) 4.7 (1.5) 7.4 (1.7) 1.8 (0.5) 3.5 (I.0) 1.5 (0.9) 
VPA--baseline 0.6 (0.04) 5.5 (0.3) 2.9 (0.3) 12 (I.9) 3.1 (0.6) 
VPA-placebo 0.6 (0.03) 6.3 (0.4) 3.3 (0.3) 11 (2.3) 3.5 (0.9) 
VPA--active 0.8 (0.1) 5.9 (0.5) 2.9 (0.3) 12 (1.7) 3.4 (0.5) 
PHT--baseline 0.6 (0.1) 6.8 (0.4) 4.0 (0.3) 9 (2.4) 2.2 (0.3) 
PHT--placebo 0.6 (0.1) 7.4 (0.5) 3.4 (0.3) 13 (2.8) 2.1 (0.3) 
PHT----active 0.6 (0.1) 6.4 (0.4) 3.6 (0.4) 10 (1.7) 2.4 (0.5) 
2.7 ( I. I ) 0.7 (0.4) 
3.9 (1.0) 0.6 (0.6) 
3.2 (0.6) 1.2 (0.8) 
2.2 (I.6) 3.6 (2.2) 
3.0 (1.5) 2.6 (1.1) 
2.5 (1.1) 4.3 (1.9) 
extinguish a light in response to its appearance atone 
of six target markers. The decision time was the time 
taken to respond to the light coming on by removing 
the finger from the base button. The mean of 30 trials 
was recorded for both. 
Fingertapping. This involved counting the number of 
taps/min achieved by the dominant index finger on a 
calculator button in constant addition mode. A series 
of practice runs was allowed before final scoring. 
Digitspan. Patients first recalled a maximum number 
of digits in ascending order following an oral presen- 
tation. This process was then repeated with digits in 
a reverse order. The patient was allowed two trials at 
each level and the task was discontinued when both 
were failed. 
Visual span. Patients were presented with a series of 
words which they were asked to recall, initially in or- 
der of presentation (forward span) and subsequently 
in reverse order (backward span). They were allowed 
two trials at each level, and the task was discontinued 
when both were failed. 
Word-pairlearning. This involved counting the num- 
ber of trials which each patient required to reach the 
target of three correct pairings when associating un- 
related words. 
Symptomatology. Questionnaires were completed re- 
questing details on possible AED adverse ffects of 
headache, dizziness, itch, diplopia, ataxia, dry mouth, 
breathlessness, nausea nd palpitations. These symp- 
toms were rated 'none, mild, moderate or severe'. 
Subjective scores of sedation, memory, concentration 
and mood were obtained on 10 cm visual analogue 
scales. 
Analysis 
Blood samples were taken into hep~-inized tubes, 
centrifuged immediately and the plasma stored at 
-20  °C for batch analysis. CBZ, VPA and PHT con- 
centrations were obtained by enzyme immunoassay 
(EMIT, Syva, Palo Alto, USA). AED concentrations 
were compared using students' two-sample t-test. 
Multivariant statistical analysis was performed for 
the cognitive function tests using MINITAB for Win- 
dows statistical package (Version 10.1) on a Viglen 
4DX266 "microcomputer. 
RESULTS 
Twelve patients received active treatment first with 11 
taking placebo. Plasma AED levels were statistically 
significantly higher during the active treatment phases 
at days 7 and 28 compared with the placebo treatment 
phases (Table 1). Seizure frequency (mean-I-SEM) 
was better on the active treatment month for all three 
drugs (CBZ: active 0.5 4- 0.34, placebo 0.6 4- 0.4; 
VPA: active 0 4- 0, placebo 0.38 4- 0.38; PHT: ac- 
tive 0.2 4- 0.2; placebo 2.2 4- 1.9). Only five patients 
subsequently stayed on the increased ose of their 
medication (3 CBZ, 1 VPA, 1 PHT). No significant 
change was observed in any cognitive test comparing 
active treatment with placebo at any time point for 
the three drugs analysed together and separately. Se- 
lected results are shown in Table 2. A complete data 
set can be obtained on request from the authors. 
DISCUSSION 
It can be anticipated that as the incidence of epilepsy 
in the elderly continues to rise, the potential dele- 
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terious effects of AEDs will assume increasing 
importance 23. It is generally held that cognitive func- 
tion in the elderly is particularly susceptible to the 
adverse effects of AEDs 9. During this small double- 
blind randomized study, we were able to achieve 
clinically and statistically relevant increases in AED 
plasma levels with patients taking a modest extra 
dose of CBZ, VPA or PHT during the active treat- 
ment phase. Despite concentrations often in the upper 
reaches of the relevant target ranges for the drugs 24, 
we found no significant alteration in cognitive func- 
tion when comparing active with placebo treatments 
both overall and for each individual drug. Patients 
with poorly controlled epilepsy were not included to 
avoid the potential confounding factor of seizure ac- 
tivity. 
In a recent survey of prescribing practice of UK 
geriatricians, CBZ and PHT were most often pre- 
scribed first, with VPA largely second choice 25. We 
have previously demonstrated in younger patients that 
VPA has little significant impact on cognitive func- 
tion in therapeutic dosage, but found that CBZ tended 
to adversely influence psychomotor activity and PHT 
memory 18. More recently, however, Craig and Tallis 6 
reported that VPA and PHT had little effect on cog- 
nitive function in older people. Older patients taking 
standard AEDs do not necessarily develop cognitive 
impairment when the dose of their medication is mod- 
estly increased within the target ranges for the drugs. 
Further studies are required with both the newer and 
established AEDs in this vulnerable population of pa- 
tients. 
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